Pediatric Preclinical Testing Consortium evaluation of the AZD1775 as a single agent and in combination with irinotecan

被引：1
|
作者：
Houghton, Peter J. [1 ]
Kurmasheva, Raushan T. [1 ]
Gorlick, Richard [2 ]
Kolb, E. Anders [3 ]
Mosse, Yael P. [4 ]
Erickson, Stephen W. [5 ]
Guo, Yuelong [5 ]
Teicher, Beverly A. [6 ]
Smith, Malcolm A. [6 ]
Maris, John M. [4 ]
机构：
[1] Greehey Childrens Canc Res Inst, San Antonio, TX USA
[2] MD Anderson, Houston, TX USA
[3] Nemours Ctr Canc & Blood Disorders, Wilmington, DE USA
[4] Childrens Hosp Philadelphia, Philadelphia, PA 19104 USA
[5] RTI Int, Res Triangle Pk, NC USA
[6] NCI, Bethesda, MD 20892 USA
来源：
MOLECULAR CANCER THERAPEUTICS | 2018年 / 17卷 / 01期
关键词：
D O I：
10.1158/1535-7163.TARG-17-LB-B15
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
LB-B15
引用
收藏
页数：2
相关论文
共 50 条
  • [41] Evaluation of the TPO-receptor agonist Eltrombopag in the Pediatric Preclinical Testing Consortium osteosarcoma in vivo models.
    Roth, Michael
    Nevil, Grace
    Gill, Jonathan Benjamin
    Zhang, Wendong
    Teicher, Beverly A.
    Erickson, Stephen W.
    Gatto, Gregory
    Smith, Malcolm A.
    Kolb, E. Anders
    Gorlick, Richard Greg
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [42] Antitumor activity of the WEE1 inhibitor AZD1775 as a monotherapy and in combination with the PARP inhibitor olaparib in patient-derived explant (PDX) models
    O'Connor, M. J.
    Odedra, R.
    Palakurthi, S.
    Hughes, A.
    Lai, Z.
    Kirschmeier, P.
    Zeng, Q.
    Zhou, S.
    Dharma, S.
    Ivanova, E.
    Wang, A.
    Pierce, A. J.
    Yates, J.
    Powell, S.
    Dougherty, B.
    Barrett, J. C.
    English, J.
    Jewsbury, P.
    Matulonis, U. A.
    Liu, J. F.
    EUROPEAN JOURNAL OF CANCER, 2016, 69 : S142 - S142
  • [43] Phase I Study Evaluating WEE1 Inhibitor AZD1775 As Monotherapy and in Combination With Gemcitabine, Cisplatin, or Carboplatin in Patients With Advanced Solid Tumors
    Leijen, Suzanne
    van Geel, Robin M. J. M.
    Pavlick, Anna C.
    Tibes, Raoul
    Rosen, Lee
    Razak, Albiruni R. Abdul
    Lam, Raymond
    Demuth, Tim
    Rose, Shelonitda
    Lee, Mark A.
    Freshwater, Tomoko
    Shumway, Stuart
    Liang, Li Wen
    Oza, Amit M.
    Schellens, Jan H. M.
    Shapiro, Geoffrey I.
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (36) : 4371 - +
  • [44] Pediatric preclinical testing consortium evaluation of the EZH2 inhibitor tazemetostat in orthotopic PDX models of pediatric brain tumors.
    Li, Xiao-Nan
    Qi, Lin
    Kogiso, Mari
    Lindsay, Holly Brianne
    Erickson, Stephen W.
    Guo, Yuelong
    Smith, Malcolm A.
    Teicher, Beverly A.
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [45] ATM kinase inhibitor AZD0156 in combination with irinotecan and 5-fluorouracil in preclinical models of colorectal cancer
    S. Lindsey Davis
    Sarah J. Hartman
    Stacey M. Bagby
    Marina Schlaepfer
    Betelehem W. Yacob
    Tonia Tse
    Dennis M. Simmons
    Jennifer R. Diamond
    Christopher H. Lieu
    Alexis D. Leal
    Elaine B. Cadogan
    Gareth D. Hughes
    Stephen T. Durant
    Wells A. Messersmith
    Todd M. Pitts
    BMC Cancer, 22
  • [46] ATM kinase inhibitor AZD0156 in combination with irinotecan and 5-fluorouracil in preclinical models of colorectal cancer
    Davis, S. Lindsey
    Hartman, Sarah J.
    Bagby, Stacey M.
    Schlaepfer, Marina
    Yacob, Betelehem W.
    Tse, Tonia
    Simmons, Dennis M.
    Diamond, Jennifer R.
    Lieu, Christopher H.
    Leal, Alexis D.
    Cadogan, Elaine B.
    Hughes, Gareth D.
    Durant, Stephen T.
    Messersmith, Wells A.
    Pitts, Todd M.
    BMC CANCER, 2022, 22 (01)
  • [47] Initial Testing (Stage 1) of AZD6244 (ARRY-142886) by the Pediatric Preclinical Testing Program
    Kolb, E. Anders
    Gorlick, Richard
    Houghton, Peter J.
    Morton, Christopher L.
    Neale, Geoffrey
    Keir, Stephen T.
    Carol, Hernan
    Lock, Richard
    Phelps, Doris
    Kang, Min H.
    Reynolds, C. Patrick
    Maris, John M.
    Billups, Catherine
    Smith, Malcolm A.
    PEDIATRIC BLOOD & CANCER, 2010, 55 (04) : 668 - 677
  • [48] Initial testing (stage 1) of the mTOR kinase inhibitor AZD8055 by the pediatric preclinical testing program
    Houghton, Peter J.
    Gorlick, Richard
    Kolb, E. Anders
    Lock, Richard
    Carol, Hernan
    Morton, Christopher L.
    Keir, Stephen T.
    Reynolds, C. Patrick
    Kang, Min H.
    Phelps, Doris
    Maris, John M.
    Billups, Catherine
    Smith, Malcolm A.
    PEDIATRIC BLOOD & CANCER, 2012, 58 (02) : 191 - 199
  • [49] Preclinical profile of docetaxel (Taxotere): Efficacy as a single agent and in combination
    Bissery, MC
    Vrignaud, P
    Lavelle, F
    SEMINARS IN ONCOLOGY, 1995, 22 (06) : 3 - 16
  • [50] Pediatric Preclinical Testing Consortium evaluation of a DLL3-targeted antibody drug conjugate rovalpituzumab tesirine, in neuroblastoma
    Sano, Renata
    Krytska, Kateryna
    Tsang, Matthew
    Erickson, Stephen W.
    Teicher, Beverly A.
    Saunders, Laura
    Jones, Ryan T.
    Smith, Malcom A.
    Maris, John M.
    Mosse, Yael P.
    CANCER RESEARCH, 2018, 78 (13)
12345